1 CoBRA: Containerized Bioinformatics workflow for

2 **Reproducible ChIP/ATAC-seq Analysis - from differential peak** 2 calling to pathway analysis

calling to pathway analysis 3 Xintao Qiu^{1,2,#}, Avery S. Feit^{2,3,#}, Ariel Feiglin^{4,#}, Yingtian Xie¹, Nikolas Kesten¹, Len 4 Taing^{1,5}, Joseph Perkins¹, Ningxuan Zhou¹, Shengqing Gu⁵, Yihao Li², Paloma Cejas^{1,2}, 5 Rinath Jeselsohn², Myles Brown^{1,2}, X. Shirley Liu^{1,5}, Henry W. Long^{1,2*} 6 7 , 8 9 1 Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA 2 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 10 02215, USA 3 Albert Einstein College of Medicine, The Bronx, NY, 10461 USA 11 12 13 4 Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02215, USA. 5 Department of Data Sciences, Dana Farber Cancer Institute, Harvard T.H. Chan School of Public Health, 14 Boston, MA 02215, USA. 15 *Correspondence: Henry Long@dfci.harvard.edu 16 17 18 #Equal contributors 19 KEYWORDS: ChIP-seq, ATAC-seq, Snakemake, Docker, workflow 20 21 22 Word Counts: 23 **ABSTRACT: 118** 24 ARTICLE: 3593 25 26 **REFERENCES: 27** 27 FIGURES: 4 28 TABLES: 1 29 SUPPLEMENTARY FIGURES: 3 30 SUPPLEMENTARY TABLES: 0 31 32 33 34 35 Running Title: "CoBRA: Containerized analysis for ChIP/ATAC-seq" 36

37 Abstract

38 ChIP-seq and ATAC-seq have become essential technologies used as effective methods of

39 measuring protein-DNA interactions and chromatin accessibility. However, there is a need

40 for a scalable and reproducible pipeline that incorporates correct normalization between

41 samples, adjustment of copy number variations, and integration of new downstream analysis

42 tools. Here we present CoBRA, a modularized computational workflow which quantifies

43 ChIP and ATAC-seq peak regions and performs unsupervised and supervised analysis.

44 CoBRA provides a comprehensive state-of-the-art ChIP and ATAC-seq analysis pipeline that

45 is usable by scientists with limited computational experience. This enables researchers to gain

46 rapid insight into protein-DNA interactions and chromatin accessibility through sample

47 clustering, differential peak calling, motif enrichment, comparison of sites to a reference DB48 and pathway analysis.

48 49

50 Code availability: https://bitbucket.org/cfce/cobra

51 Introduction

52 ChIP-seq and ATAC-seq have become essential components of epigenetic analysis. They are 53 employed extensively in the study of protein-DNA interactions and chromatin accessibility 54 respectively. Chromatin immunoprecipitation sequencing (ChIP-seq) is a high-throughput 55 technology that provides unique insights into protein function by mapping genome wide 56 binding sites of DNA-associated proteins. Further, Assay for Transposase-Accessible 57 Chromatin sequencing (ATAC-seq) is a high-throughput technology that is imperative in the 58 assessment of genome-wide chromatin accessibility. While numerous pipelines for analyzing 59 ChIP-seq and ATAC-seq data have been reported in the literature [1-8] there remains a 60 strong need for pipelines that can be run by users who have less experience utilizing computational biology tools. Comparisons between ChIP and ATAC-seq experiments can 61 62 provide insight into differences in protein occupancy, histone marks and chromatin 63 accessibility (Figure 1a), however, existing analysis pipelines can lack useful components 64 necessary in the analysis. There is a need for better normalization between samples, 65 adjustment of copy number variations, integrating new downstream analysis tools such as 66 cistromeDB Toolkit [9] and integrating epigenetic data with RNA-seq.

67

68 In this work we developed CoBRA (Containerized Bioinformatics workflow for

69 Reproducible ChIP/ATAC-seq Analysis), a modularized computational workflow which

70 quantifies ChIP and ATAC-seq peak regions and performs unsupervised and supervised

71 analysis. The pipeline provides sample clustering, differential peak calling, motif enrichment

and clustering, comparison of sites to a reference DB and pathway analysis. In addition, it

73 provides clear, high-quality visualizations for all results.

74

CoBRA uses Snakemake [10], a workflow management system to create the computational
 pipeline. Using Snakemake system enables the reproducibility and scalability of CoBRA.

77 This framework allows for the addition or replacement of analysis tools as well as for the

parallelization of computationally intensive processes. To make CoBRA portable, the

79 workflow and its software dependencies are available as a Docker container, which can be

80 used on any machine with Docker installed. This includes local servers, high-performance

81 clusters, and cloud-based machines. Docker will automatically download all required

82 software dependencies because the container encapsulates all of the supporting software and

- 83 libraries, eliminating the possibility of conflicting dependencies.
- 84

- 85 CoBRA therefore provides solutions to challenges inherent in many bioinformatics
- 86 workflows: it is portable, reproducible, scalable and easy to use. It is open source
- 87 (https://bitbucket.org/cfce/cobra) and well documented online including step-by-step tutorials
- 88 that go through all three case studies presented in this paper (https://cfce-
- 89 cobra.readthedocs.io). This combination of features enables researchers to gain rapid insight
- 90 into protein-DNA interactions and chromatin accessibility with comprehensive state-of-the-
- 91 art ChIP and ATAC-seq analysis.

92 **Methods**

93 Overall design

- 94 The CoBRA pipeline is implemented using the snakemake workflow management system
- 95 [10] and is described via a human-readable, Python-based language. This allows CoBRA to
- 96 scale to server, cluster, grid and cloud environments, without the need to modify the
- 97 workflow. For ChIP-seq and ATAC-seq experiments, CoBRA provides both unsupervised
- 98 and supervised analyses (Figure 1b). It does not include preprocessing ChIP and ATAC-seq
- 99 quality control steps as this is best handled within other, specialized pipelines [11].
- 100

101 Further, CoBRA is distributed as a Docker container, which can be used on any machine as

- 102 long as Docker is installed. Docker containers provide a tool for packaging bioinformatics
- 103 software. It encapsulates all of the supporting software and libraries, eliminates the possibility
- 104 of conflicting dependencies, and facilitates the installation of required software. With the
- 105 built-in snakemake reference rule, CoBRA automatically downloads all needed reference
- 106 files if they have not been downloaded. As a result, CoBRA is reproducible, portable and
- 107 easy to deploy. Users specify analysis parameters in a simple human readable configuration
- 108 file (Supplementary Fig1b). A separate file contains metadata about the samples being 109
- analyzed (cell line, treatment, time point, etc.) as well as a specification of the differential 110
- comparisons to be performed by the pipeline. This metadata file is in CSV format and can be
- easily modified in any standard text editor or Excel. 111
- Unsupervised analysis 112

113 The pipeline calculates the Reads per Kilobase per Million Mapped Reads (RPKM) using bed

114 files and bam files provided by the user to normalize for sequencing depth and peak size. The

- 115 RPKM table is filtered through the removal of sites that have low RPKM across multiple
- 116 samples. Quantile Normalization (default), Z-score, Log transform are available options to
- 117 normalize the count matrix. To visualize the similarities between samples in the experiment,
- 118 sample-sample correlation, principal component analysis (PCA) and sample-feature plot are
- 119 automatically generated by the pipeline.
- 120

The sample-sample correlation plot illustrates the similarity between all of the samples on a 121

122 pairwise basis. It also provides the clustering result based on the Pearson correlation

123 coefficient, r, where distance = 1 - r. The user can opt for using spearman correlation as well

- 124 as selecting other distance methods (euclidean, manhattan, canberra, binary, maximum, or
- 125 minkowski) by simply changing the configuration file. The resulting correlation plot helps to
- 126 determine whether the different sample types can be separated, i.e., samples of different
- 127 conditions are expected to be more dissimilar to each other than replicates within the same
- 128 condition. User provided metadata are used to automatically annotate samples in all
- 129 unsupervised plots.
- 130

131 Further, CoBRA will produce a principal component analysis (PCA) plot depicting how

132 samples are separated in the first two principal components (those with the largest variance)

and samples will be automatically color-coded by all user provided annotations. The PCA

134 plot helps the user to determine if any patterns exist between the samples and if outliers are

135 present. Finally, CoBRA will generate a Sample-Feature heatmap. The heatmap illustrates the

136 clustering of samples based on correlation on the horizontal axis and clustering of peaks on

the vertical axis. Peaks on the vertical axis can be clustered by hierarchical or k-means

138 clustering. The sample-feature heatmap elucidates patterns of peaks across samples and

139 identifies the clusters that are enriched in a subset of samples.

140 Supervised analysis

141 A common question being asked is what the differential sites are (TF binding/ histone

142 modification/ chromatin accessibility) between sample groups. Several tools (DEseq2,

edgeR, Limma) currently available can be applied to analyze differential sites, most of which

are derived from RNA-seq count analysis. However, there are differences between the RNA-

seq and ChIP-seq count analysis. In RNA-seq experiments, most reads are in the exome,

146 where reads can be normalized by the total number of reads mapped to all genes. In contrast,

147 most ChIP-seq reads are outside of peaks. The FRiP score (fraction of reads in peaks)

typically ranges from 1 to 40 percent [11]. Reads in peaks are only a portion of total reads that have been sequenced. Therefore, all reads need to be normalized by the total number of

149 uniquely mapped reads to account for sequence depth. CoBRA uses the bam file to calculate

151 sequencing depth. It utilizes sequencing depth as a scale factor in differential peak calling by

152 DESeq2 (although the user can specify reads in peaks for scaling if specifically required).

153 This is an essential step in differential peak calling. The default scale factor utilized by

154 DESeq2 to normalize the data is the total number of reads mapped to peaks. This method can

result in the calling of false positive differential peaks. Using sequencing depth as the scale

156 factor ensures that reads are normalized for experimental variation and not biological 157 variation between samples.

158

159 Multiple comparisons can be done within a single run. For each comparison, the number of 160 differential peaks for two adjusted p-value cutoffs and two fold-change cut-offs will be 161 displayed in a summary chart. Further, the bigwig files are used to plot the peak intensity of

162 the differential peaks in a heatmap using deepTools2 [12].

163

The differentially enriched regions from DEseq2 for each comparison are subsequently run through HOMER [13] for motif enrichment analysis. Motif enrichment analysis is a fundamental approach to look for transcription factor motifs that might be enriched in peaks

167 of interest. We use Homer in the pipeline to look for known and de novo motifs that are

167 of interest. We use Homer in the pipeline to look for known and de novo motifs that are 168 enriched in the differential peak regions compared to GC matched, randomly selected

169 genome background. In addition, we utilize a motif clustering algorithm to organize various

170 motifs by similarity making the output (Supplementary Figure 3) easier to evaluate for

distinct results. By mapping the peaks to the nearest gene, CoBRA uses GSEA pre-ranked

analysis to investigate the pathways that are enriched and depleted for both up and down

- 173 peaks.
- 174

175 The up and down-regulated sites are also automatically compared to a comprehensive

176 database of ChIP/ATAC and DNase data [9; 14]. This Cistrome Toolkit analysis determines

177 the most similar samples in terms of genomic interval overlaps with the differential sites. The

toolkit is particularly useful to identify the major transcription factors related to the

179 differential perturbations. In addition, it can be useful in the identification of the potential

180 biological source (cell line, cell type and tissue type) of the regions of interest.

181 **Results**

182 In order to illustrate the utility of CoBRA, we applied it to three projects with components

183 that illustrate the different capabilities of our workflow: a GR ChIP-seq data set from the

184 ENCODE project, H3K27ac ChIP-seq data from colon cancer cell lines, and an ATAC-seq

185 experiment on HL-60 promyelocytes differentiating into macrophages. Each example

186 demonstrates some key functions of the CoBRA pipeline.

187 Case Studies

188 Example 1: Normalizing GR ChIP-seq data in a dose-response experiment

189 We downloaded publicly available glucocorticoid receptor (GR) ChIP-seq data (<u>GSE32465</u>)

190 from a lung adenocarcinoma cell line (A549) at 3 different concentrations of dexamethasone,

a potent GR agonist. In an analysis of this dataset [15], it was found that the number of

192 Glucocorticoid Receptor (GR) binding sites increases with increasing dexamethasone

193 concentration. In the experiment, samples were treated with 0.5nM, 5nM, or 50nM of

194 dexamethasone. CoBRA's unsupervised analysis showed that the sample replicates cluster

195 tightly together. Similarities and differences between samples are illustrated by the

196 correlation between treatments vs within treatment in the dendrogram at the top of sample-

- 197 sample heatmap (Figure 2a), as well as the principal component plot (Supplementary Figure1).
- 198 199

While unsupervised analyses are useful, the advantage of the CoBRA pipeline is its ability to 200 201 accurately call differential peaks accounting for a variety of factors. We applied DESeq2 to 202 assess the differences in peak binding for samples treated with 50nM of dexamethasone 203 versus samples treated with 0.5nM of dexamethasone. Utilizing DESeq2's default scale 204 factor method which normalizes the data using the total number of reads in peaks, differential 205 peaks are called (Figure 2b) where they are clearly not present (Figure 2c left). A group of 206 peaks at the bottom of the figure 2c exhibit similar binding intensity, however, they are 207 considered downregulated in 50nM treatment in the DEseq2 result.

208

209 DEseq2 by default normalizes all samples by total reads in the read count table. In RNA-seq, 210 most reads are in the exome, where reads can be normalized by the total number of reads 211 mapped to all genes. In contrast, in the GR ChIP-seq experiment, samples treated with 50nM 212 dexamethasone exhibit much greater GR binding and the FRiP score is higher than samples 213 treated with 0.5nM (9.3 vs 0.9). Therefore, DESeq2's normalization method decreases the 214 peak intensity in the 0.5nM treated samples because the FRiP scores are higher in the 50nM 215 sample resulting in false positive differential peaks (Figure 2c right). In CoBRA, we use a 216 scaling factor dependent on the sequencing depth of each sample. This eliminates the false 217 positive downregulated peaks called by DESeq2 using the default scaling factor (Figure 2c 218 right and Figure 2b). Furthermore, more real differential gained peaks have been successfully 219 identified with CoBRA's scaling method.

220

An additional feature of CoBRA is that it automatically analyzes the differential peaks to provide additional insight into their origin and identify similar systems in the literature. In

one analysis it determines the most similar ChIP-seq data that is available in a large, curated

224 database of ChIP and ATAC data - cistrome.org [14]. For the gained GR binding sites in the

dexamethasone treatment, the result from the Cistrome Toolkit [9] clearly shows that the

226 *NR3C1* in lung tissue is the most similar ChIP-seq in the cistrome database (Figure 2d).

227 CoBRA provides a list of GEO accession numbers corresponding to all ChIP-seq data with

similarity to the differential peak set. Using these identifiers, ChIP seq data of interest can be

downloaded for further investigation from Cistrome DB[14]. While obviously correct in this

simple case, this tool can provide unique insight into gained or lost sites such as identifying

which transcription factor potentially binds to a differential peak set after a perturbation and

in investigating similar cellular systems. In addition, CoBRA performs a de novo motif

analysis on differential sites which can help to identify potential transcriptional regulators

enriched in our differentially accessible chromatin elements. In this example the top cluster

has all hormone receptor motifs enriched in the upregulated peaks.

236 Example 2: Correcting for Copy Number variation in H3K27ac ChIP-seq

237 We further illustrate the advantages of the CoBRA pipeline utilizing data from colorectal

238 cancer cell lines. Microsatellite Instable (MSI) and Microsatellite Stable (MSS) are two

239 classes used to characterize colorectal cancers. To analyze these cell lines, we selected six

240 publicly available datasets from several experiments: three MSI samples and three MSS

241 samples [16-20] (<u>GSM1866974</u>, <u>GSM2265670</u>, <u>GSM1224664</u>, <u>GSM1890746</u>,

- 242 <u>GSM2058027</u>, <u>GSM1890746</u>).
- 243

MSS tumors are one of the most highly mutated tumor types [21] and typically exhibit a high 244 245 number of copy number alterations. Without adjustment, a differential peak caller will rank 246 peak loci with high copy number gain in MSS as being the most differential compared to 247 MSI. These genetic differences, while important, can obscure important epigenetic 248 differences between MSI and MSS. In order to observe differential peaks other than those 249 called as a result of the presence of CNV, copy number variation adjustment was conducted 250 on all samples. For this example the copy number was called using the ChIP-seq data itself 251 with CopywriteR [22] but can also be done with qDNAseq [23] using the input control if 252 available. Any other source of CNV data can also be used when put in a standard igv format. 253 This CNV adjustment alters the differential peaks called by DESeq2. In the case of the MSS 254 vs. MSI comparison, many peaks at the 8q region of the chromosome are being called 255 significantly differential (Figure 3a) but, following CNV correction, the number of

256 differential peaks in this region significantly decreased (Figure 3b).

257

Gene Set Enrichment analysis is performed on the ranked list of genes produced by CoBRA.
 Without CNV adjustment, GSEA can indicate greatest enrichment in gene sets solely related

to amplification. As a result, it is challenging to assess the true epigenetic differences

between the two colorectal cancer types. For instance, the gene set

262 'NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON' includes genes up-regulated in non-

263 metastatic breast cancer tumors with amplification in the 8q22 region. Without adjustment for

copy number variation, this gene set is significantly enriched (Figure 3c). It is the 3th ranked

265 gene, with a normalized enrichment score of -2.84 and an adjusted p-value less than 0.0001.

266 With CNV adjustment, this gene set is far less enriched (Fig. 3c). It is the 468th ranked gene

set and has a normalized enrichment score of -1.32 and an adjusted p-value of 1.

268

269 After CNV correction, the Hallmarks GSEA analysis shows that the MSI cell line has

270 enrichment in the following pathways: TNFA signaling via NFKB, TFG beta signaling, and

271 Inflammatory response (Figure 3d). This is consistent with the literature[24-25] in reference

to colon cancer with MSS tumors exhibiting more inflammatory signaling.

273 Example 3: Unsupervised analysis of time series ATAC-seq data

274 In this example, we illustrate the efficacy of CoBRA's analysis of ATAC-seq experiments by

following the chromatin accessibility profile of differentiating cells [26]. In this experiment

researchers utilized a five-day time course (0hr, 3hr, 24hr, 96hr, and 120hr) to profile

277 accessible chromatin of HL-60 promyelocytes differentiating into macrophages (GSE79019).

The CoBRA output includes a principal component analysis (PCA) plot (Figure 4a) that demonstrates the temporal differentiation of the macrophages; the early time point is on the left side while the late time point is on the right. Furthermore, the output includes a samplefeature heatmap utilizing k-means (k=3) clustering (Figure 4b) that further illustrates the dramatic differences in open chromatin profiles. The three clusters show clear differences in

adamate differences in open chromatin profiles. The three clusters show clear differences in
 open chromatin between the early (cluster 1), intermediate (cluster 2), and late stage (cluster
 3) time points.

285

CoBRA automatically performs a de novo motif analysis on each of the three clusters of
accessible sites to identify motifs of potential transcriptional regulators enriched in
differentially accessible chromatin elements. This analysis identified many transcription
factor motifs enriched in each cluster (Figure 4c). Motifs for PU.1, RUNX and MYB were
enriched in cluster 1, which exhibits a decrease in accessibility during myeloid
differentiation. It is likely that a depletion of PU.1, RUNX and MYB occupancy occurs at

these elements during cellular commitment. In addition, we observe the EGR and MAF

293 motifs in clusters 3 suggesting a gain of EGR and MAF occurs at these elements during

294 macrophage differentiation. The motif analysis for cluster 2 also identified chromatin element

NFKB and NFE2 as being active during differentiation and depleted in the latter stages. All

296 of these findings are consistent with the results from published papers [26].

297

298 Finally, ChIP-seq and ATAC-seq data is often generated in parallel with RNA-seq on the

same samples. An extension to CoBRA can take the differential expression gene list from

RNA-seq analysis tools such as VIPER [27] and highlight differentially expressed genes that also exhibit differential chromatin accessibility. The volcano plot in Figure 4d is a

302 visualization of the genes differentially expressed during macrophage differentiation and

303 highlights those genes that also have nearby opening chromatin during differentiation. Genes

304 near open chromatin during differentiation are more likely to be upregulated. This profile that

305 combines chromatin accessibility with gene expression can provide insight to potentially

306 identify major transcriptomic elements driving differentiation.

307 **Discussion**

The case studies that we have presented highlight typical use cases for CoBRA. The first example is accurate identification of differential peaks using appropriate normalization of ChIP-seq data. Some methods fail to normalize correctly in calling differential peaks when the FRiP score is impacted by perturbations. CoBRA reduces false positives and identifies more true differential peaks by correctly normalizing for sequencing depth.

313

The second example demonstrates how CoBRA can be used to account for amplification due to copy number variation present in experimental samples. This is an important feature, as

316 copy number variation can drive the greatest differences between some tumor samples and

317 obscure other biological changes to the cistrome that occur as a result of treatment or other

318 experimental conditions. After adjustment of CNV, differential peaks called by DESeq will

319 not be affected by amplification between samples, allowing biologists to better understand

320 whether differences are caused by changes in the genetic or epigenetic landscape.

321

322 The third example illustrates how CoBRA can be applied to ATAC-seq experiments.

323 Unsupervised analyses can identify changes in the chromatin accessibility over time with

324 treatment, and clustering provides insight into similarities and differences between samples

and the investigation of the transcription factor motif enrichment in each cluster.

326

327 The application of CoBRA to these experiments demonstrate the broad capabilities of the workflow in analyzing ChIP-seq or ATAC-seq experiments. While other workflows used to 328 329 analyze ChIP or ATAC experiments exist, they lack some of the features present in CoBRA 330 (table 1). Additionally, the highly modular Snakemake framework allows for rapid 331 integration of new approaches or replacement of existing tools. Modules can be added simply 332 by adding a new Snakemake "rule" and adding a flag in the config file (Supplementary 333 Figure 2a-c) to turn the analysis on. Further, CoBRA's "rules" can be composed of tools written in R, Python, or shell script. The framework allows for great flexibility because each 334 335 module can be evaluated in its own environment using different tools (e.g. Python 2.7 and 336 Python 3 based software).

337

The methods for installing, deploying, and using CoBRA along with a detailed tutorial are
provided in the documentation available online(<u>https://cfce-cobra.readthedocs.io/</u>). The
workflow was designed to work with Docker, which allows the user to automatically
download all required software dependencies, eliminating the possibility of conflicting

- 342 dependencies. This makes CoBRA easy for those with limited computational training to
- install and run the workflow. Furthermore, the user does not need to prepare any reference
- files, as CoBRA automatically downloads all needed reference files. As a result, CoBRA is
- 345 portable, reproducible and easy to deploy.
- 346 347

Pipelines Features	CoBRA	Diffbind	HMCan- diff	ChIPcomp	Deeptools	esATAC	OPENANNO
Sample-sample Correlations	1		\checkmark		\checkmark	~	
Sample-feature Clustering	\checkmark	\checkmark			\checkmark		
PCA analysis	\checkmark	\checkmark					
Normalize based on Sequencing Depth	1	\checkmark					
CNV Correction for Differential Peak Calling	~		\checkmark				
Motif Analysis	\checkmark					~	

Pathway Analysis	\checkmark				✓	
Package Easy Update	\checkmark	\checkmark	\checkmark		~	1
Easy Support New Species	\checkmark					
Docker Containerized	~					
Annotate Peak Regions with Public ChIP-seq database	~					1
Step-by-Step Tutorial with Multiple Case Studies	~	~		~	~	

348

349 Table 1. A comparison of the features of CoBRA with other available pipelines.

350

In summary we have developed a new pipeline, CoBRA (Containerized Bioinformatics

351 workflow for Reproducible ChIP/ATAC-seq Analysis), that is fast, efficient, portable, 352

customizable and reproducible. The workflow builds upon the ongoing effort to make 353

354 computational research reproducible using defined workflows running inside Docker

355 containers. CoBRA allows users of varying levels of technical skill to quickly process and

356 analyze new data from ChIP-seq and ATAC-seq experiments. It is the authors' hope that

357 CoBRA can be a starting point for others to build upon and improve CoBRA as a tool and 358 extend its ability to analyze the cistrome.

359

Availability of data and software 360

361 The dataset(s) supporting the conclusions of this article are all publicly available in the NCBI

- Sequence Read Archive as referenced in the text. 362
- 363
- 364 The software described in this article is publicly available online.
- 365 Project name: CoBRA.
- Project home page: https://bitbucket.org/cfce/cobra, https://cfce-cobra.readthedocs.io 366
- Archived version: publication. 367
- 368 Operating system(s): UNIX; MacOS.
- 369 Programming language: multiple.

- 370 Other requirements: Docker, wget, git, miniconda3.
- 371 License: GNU GPL.
- 372 Any restrictions to use by non-academics: N/A.
- 373
- 374

375 **CRediT author statement**

- 376 Xintao Qiu: Methodology, Software, validation, Writing Original Draft
- 377 Avery S. Feit: Methodology, Software, validation, Writing Original Draft
- 378 Ariel Feiglin: Methodology, Software, validation
- 379 Yingtian Xie: Validation, Data Curation
- 380 Nikolas Kesten: Validation
- 381 Len Taing: Software, Validation
- 382 Joseph Perkins: Software
- 383 Ningxuan Zhou: Validation, Investigation
- 384 Shengqing Gu: Validation, Investigation
- 385 Yihao Li: Validation, Investigation
- 386 Paloma Cejas: Validation, Investigation
- 387 Rinath Jeselsohn: Resources, Validation
- 388 Myles Brown: Conceptualization, Supervision, Funding
- 389 X. Shirley Liu: Supervision, Project Administration
- 390 Henry W. Long: Supervision, Funding, Conceptualization, Writing Review & Editing
- 391

392 **Competing Interests**

393 The authors have declared that no competing interests exist.

394 Acknowledgements

- 395 H.W.L. and M.B. acknowledge funding from the National Institutes of Health (USA) grant
- 396 2PO1CA163227.
- 397

398 Authors' ORCID IDs

- 399 Xintao Qiu 0000-0002-8560-7017
- 400 Paloma Cejas 0000-0002-8417-4811
- 401 Rinath Jeselsohn 0000-0001-7996-7529
- 402 Myles Brown 0000-0002-8213-1658
- 403 X. Shirley Liu 0000-0001-8588-1182
- 404 Henry W. Long 0000-0001-6849-6629
- 405
- 406

407

408 **References**

- 409 1. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, et al.
- 410 Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.

- 411 Nature. 2012;481:389–93.
- 412 2. Ashoor H, Hérault A, Kamoun A, Radvanyi F, Bajic VB, Barillot E, et al. HMCan: a
- 413 method for detecting chromatin modifications in cancer samples using ChIP-seq data.
- 414 Bioinformatics. 2013;29:2979–86.
- 3. Allhoff M, Seré K, Chauvistré H, Lin Q, Zenke M, Costa IG. Detecting differential peaks
 in ChIP-seq signals with ODIN. Bioinformatics. 2014;30:3467–75.
- 417 4. Shen L, Shao N-Y, Liu X, Maze I, Feng J, Nestler EJ. diffReps: detecting differential
- 418 chromatin modification sites from ChIP-seq data with biological replicates. PLoS One.
- 419 2013;8:e65598.
- 5. Shao Z, Zhang Y, Yuan G-C, Orkin SH, Waxman DJ. MAnorm: a robust model for
 quantitative comparison of ChIP-Seq data sets. Genome Biol. 2012;13:R16.
- 422 6. Liang K, Keles S. Detecting differential binding of transcription factors with ChIP-seq.
 423 Bioinformatics. 2012;28:121–2.
- 424 7. Wei Z, Zhang W, Fang H, Li Y, Wang X. esATAC: an easy-to-use systematic pipeline for
 425 ATAC-seq data analysis. Bioinformatics. 2018;34:2664–5.
- 426 8. Chen S, Wang Y, Jiang R. OPENANNO: annotating genomic regions with chromatin
 427 accessibility. doi:10.1101/596627.
- 428 9. Zheng R, Wan C, Mei S, Qin Q, Wu Q, Sun H, et al. Cistrome Data Browser: expanded
 429 datasets and new tools for gene regulatory analysis. Nucleic Acids Res. 2019;47:D729–35.
- 430 10. Köster J, Rahmann S. Snakemake--a scalable bioinformatics workflow engine.
 431 Bioinformatics. 2012;28:2520–2.
- 432 11. Qin Q, Mei S, Wu Q, Sun H, Li L, Taing L, et al. ChiLin: a comprehensive ChIP-seq and
 433 DNase-seq quality control and analysis pipeline. BMC Bioinformatics. 2016;17:404.
- 434 12. Ramírez F, Ryan DP, Grüning B, Bhardwaj V, Kilpert F, Richter AS, et al. deepTools2: a
 435 next generation web server for deep-sequencing data analysis. Nucleic Acids Res.
 436 2016;44:W160–5.
- 437 13. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple Combinations
 438 of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for
 439 Macrophage and B Cell Identities. Molecular Cell. 2010;38:576–89.
- 439 Macrophage and B Cell Identifies. Molecular Ce 440 doi:10.1016/j.molcel.2010.05.004.
- 14. Mei S, Qin Q, Wu Q, Sun H, Zheng R, Zang C, et al. Cistrome Data Browser: a data
- 442 portal for ChIP-Seq and chromatin accessibility data in human and mouse. Nucleic Acids
 443 Res. 2017;45:D658–62.
- 444 15. Wu D-Y, Bittencourt D, Stallcup MR, Siegmund KD. Identifying differential
 445 transcription factor binding in ChIP-seq. Front Genet. 2015;6:169.
- 16. Tak YG, Hung Y, Yao L, Grimmer MR, Do A, Bhakta MS, et al. Effects on the
- transcriptome upon deletion of a distal element cannot be predicted by the size of the
- 448 H3K27Ac peak in human cells. Nucleic Acids Res. 2016;44:4123–33.
- 449 17. Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, et al.

Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsicpontine gliomas. Nat Med. 2017;23:493–500.

- 452 18. Maurano MT, Wang H, John S, Shafer A, Canfield T, Lee K, et al. Role of DNA
- 453 Methylation in Modulating Transcription Factor Occupancy. Cell Rep. 2015;12:1184–95.
- 454 19. McCleland ML, Mesh K, Lorenzana E, Chopra VS, Segal E, Watanabe C, et al. CCAT1
 455 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin
 456 Invest. 2016;126:639–52.
- 457 20. Rahnamoun H, Lee J, Sun Z, Lu H, Ramsey KM, Komives EA, et al. RNAs interact with
- BRD4 to promote enhanced chromatin engagement and transcription activation. Nat Struct
 Mol Biol. 2018;25:687–97.
- 460 21. Taieb J, Le Malicot K, Shi Q, Penault-Llorca F, Bouché O, Tabernero J, et al. Prognostic
- Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. J Natl
 Cancer Inst. 2017;109. doi:10.1093/jnci/djw272.
- 463 22. Kuilman T, Velds A, Kemper K, Ranzani M, Bombardelli L, Hoogstraat M, et al.
- 464 CopywriteR: DNA copy number detection from off-target sequence data. Genome Biol.465 2015;16:49.
- 466 23. Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF, et al. DNA
- 467 copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome
- sequencing with identification and exclusion of problematic regions in the genome assembly.
 Genome Res. 2014;24:2022–32.
- 470 24. Jung B, Staudacher JJ, Beauchamp D. Transforming Growth Factor β Superfamily
- 471 Signaling in Development of Colorectal Cancer. Gastroenterology. 2017;152:36–52.
- 472 doi:10.1053/j.gastro.2016.10.015.
- 473 25. Koi M, Tseng-Rogenski SS, Carethers JM. Inflammation-associated microsatellite
- 474 alterations: Mechanisms and significance in the prognosis of patients with colorectal cancer.
 475 World J Gastrointest Oncol. 2018;10:1–14.
- 26. Ramirez RN, El-Ali NC, Mager MA, Wyman D, Conesa A, Mortazavi A. Dynamic Gene
 Regulatory Networks of Human Myeloid Differentiation. Cell Syst. 2017;4:416–29.e3.
- 478 27. Cornwell M, Vangala M, Taing L, Herbert Z, Köster J, Li B, et al. VIPER: Visualization
- 479 Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis.
 480 BMC Bioinformatics. 2018;19:135.
- 481
- 482
- 483

484 **FIGURE LEGENDS**


485

- 486 **Figure 1.** Overview of CoBRA.
- 487 a) Biological motivation of CoBRA. Comparisons between ChIP and ATAC-seq peaks in
- well-designed experiments can provide insight into differences in protein occupancy,
 histone marks and chromatin accessibility.
- 490 b) Overview of the workflow performed by CoBRA. Read counts are quantified and
- 491 normalized for sequencing depth and CNV for clustering and differential peak calling
- 492 analysis. The result of differential peak calling is used downstream for motif
- 493 enrichment, GSEA, CistroneDB toolkit, and BETA analysis.
- 494
- 495 Figure 2. Example of unsupervised and supervised analysis of differential GR binding
 496 in A549 cells.
- 497 a) Sample-Sample heatmap depicting clustering and correlation between A549 cells
 498 treated with varying concentrations of dexamethasone.
- b) Visualization the differences in the GR binding between the 0.5 and 50nM samples,
- 500 plotted using mean of the peak intensities versus log2(fold change). This illustrates the
- 501 change in the inferred differential GR binding profile following normalization using
- scaling factor determined by total reads in peaks (top) and sequencing depth (bottom).
- 503 c) Deeptools heatmap illustrating differential peaks called by DESeq2 using default
- scaling factor by total reads in peaks (left) or using scaling factor determined by
- 505 sequencing depth (right). A group of peaks at the bottom of the left figure exhibit similar
- 506 binding intensity, however, they are considered downregulated in 50nM treatment in507 the default DEseq2 result.
- 508 d) Cistrome Toolkit result illustrating publicly available ChIP seq datasets ranked by 509 binding profile similarity to gained GR binding sites with dexamethasone treatment.
- 509 binding profile similarity to gained GR binding sites with dexamethasone treatment.510
- 511 **Figure 3**. Identification of differential sites correcting for copy number.
- a) Copy number distribution for an MSS sample on Chromosome 8 (top). Distribution of
- 513 differentially called peaks with (middle) and without (bottom) CNV adjustment
- 514 between MSS and MSI cell lines.
- b) Significant differential peaks in 8Q prior to CNV correction are highlighted. X axis is
- the log2 fold change and y axis is -log10 of the adjusted p-value. Left side is without CNV
- 517 correction, and the right side is with CNV correction.
- c) Enrichment plot for NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON gene set
- 519 without (left side) and with (right side) CNV adjustment.
- d) Enrichment of Hallmarks gene sets after CNV correction based on the differential
- 521 peak ranking comparing MSS with MSI.
- 522
- 523 **Figure 4**. Analysis of ATAC-seq from HL-60 promyelocytes differentiating into 524 macrophages with CoBRA.
- a) PCA plot depicting how samples cluster along the first two principal axes.
- b) Sample-Feature heatmap created by CoBRA which depicts sample clustering on the
- 527 horizontal axis and chromatin accessibility clustering on the vertical axis. Cluster 1,2,
- 528 and 3 represent sites open at early, middle and late differentiation stages respectively.
- 529 c) Motifs enriched in early, middle, and late stage differentiation identified by CoBRA.
- d) Genes differentially expressed during macrophage differentiation (120hr over 0hr).
- 531 Those genes that also have nearby differential chromatin changes during differentiation
- 532 are highlighted.
- 533

534

535 **Supplementary Figure 1.**

- a) PCA plot depicting similarity between dexamethasone treated samples. 536
- 537 b) Clustering result of the motif enrichment for sites up with 50nM treatment over 0.5nM.
- 538
- 539 540 **Supplementary Figure 2.**
- a) Example of parameter setup in config.yaml file. 541
- b) Example of parameter setup in config.yaml file. 542
- c) Example of sample path setup in config.yaml file. 543
- 544
- 545 Supplementary Figure 3. File structure of CoBRA input and output.
- 546






Figure 2




Figure 3





Figure 4



(b)

Cluster	Metif	Name	PValue	log(PValue)	# Target Sequences with Motif	% of Targets Sequences with Motif	# Background Sequences with Motif	% of Background Sequences with Motif
	<u>SAGACAJASTGTAC</u>	GRE(NR) JR3/RAW264.7-GRE-ChIP-Seq(Unpublished) Homer	le-2378	-5477,435464	3019.0	44.27%	1521.0	3.63%
	≅⊜G ⊜ACA ⊊ ≧⊊IGT⊴CZ	GRE(NR)JR3/A549-GR-ChIP-Seq(GSE32465)Homer	1e-2142	-4932.236126	2349.0	34.44%	834.5	1.97%
1	<mark>⊜G⊜ACA€≴≋TGT⊴C</mark> Z≣	AREINRO LNCAP-AR-ChIP-Seq/GSE27824)Homer	le-2031	-4677.025589	2876.0	42.17%	1742.3	4.16%
	<u><u><u>SAGAACA</u></u></u> <u>SAGAACA</u>	PGR(NR) EndeStromal-PGR-ChiP-Seq(GSE69539)/Homer	le-1835	-4225.926702	2602.0	38.15%	1540.2	3.67%
	<u>ŞAGACASIŞ TGTEÇ</u>	PRUNR/T47D-PR-ChilP-Seq(GSE31130)/Homer	le-1225	-2820.686095	5632.0	82.58%	16086.6	38.37%
2	ZÊÊTÇAÊTÇA <u>ş</u>	Fra1(bZIP/BT549-Fra1-ChIP-Seq(GSE46166)/Homer	le-1129	-2599.846466	2798.0	41.03%	3627.8	8.65%
	SEATGASTCAIS	Fra2(hZIP)/Striatum Fra2-ChIP-Seq(GSE43429)/Homer	1e-1093	-2518.963525	2590.0	37.98%	3139.8	7.49%
	Set GASTCAS	JunR(hZIP)/Dendritis/Cells-Junb-CMP-Seq(GSE36099)/Homer	1e-1040	-2396.976282	2728.0	40.00%	3729.9	8.90%
	Setgastcaise	Ad50x2IPyGBM-ATF3-ChIP-SeqG3E33912yHomer	1e-1037	-2389.268204	2975.0	43.62%	4536.5	10.82%
	TOTOTION	BATF(hZIP)/Th17-BATF-ChIP-Seq(C8E39756) Homer	le-1027	-2365.228649	2920.0	42.82%	4396.5	10.49%
	SOTGASTCASTS	Fosl2(b2IP)/JT3L1-Fosl2-ChIP-Seq(GSI56872)/Homer	1e-1015	-2338.547207	2128.0	31.20%	2151.7	5.13%
	≜TGASTCA 3⊊	AP-1(hZIP)/ThioMac-PU.1-ChIP-Seq(GSE21512)/Homer	1e-950	-2188.543174	3045.0	44.65%	5166.9	12.32%
	Set GASTCAES	Jan-AP1(623P)%562-clun ChiP-Seq(GSE31477)/Honor	1c-918	-2115.098968	1762.0	25.84%	1544.5	3.68%
	IGCTGASTCA	Bach2(bZIP) OCILg7-Bach2-ChIP-Seq(GSE44420) Homer	1e-493	-1135.631294	1172.0	17.18%	1285.2	3.07%
	<u> 숲숙순돌TGCTGAGTCA</u> 돌	Bach1(hZIP)/K562-Bach1-ChIP-Seq(OSE31477)/Homer	1e-191	-440.281436	392.0	5.75%	343.5	0.82%
	SATGACTCAGCA	NF-E2/6289yK562-NFE2-ChIP-SeqtGSE31477yHomer	1e-189	-435.587020	427.0	6.26%	422.3	1.01%
	<u><u></u>ETGCTGAGTCAI</u>	Nrf2(5ZIP)Lymphoblast-Nrf2-ChIP-Seq(GSE37589)/Homer	1c-168	-387.840346	362.0	5.31%	336.6	0.80%
	AAAIIGCTGAGTCAI	NFE2L2(hZIP)/HepG2-NFE2L2-ChIP-Seq(Encode)/Homer	1e-141	-325.917248	322.0	4.72%	330.6	0.76%
	IGCTGACICA	MafA(KZIPyIalet-MafA-ChiP-Seq(G5E30234)/Homer	1e-76	-175.974922	1475.0	21.63%	5620.6	13.41%

Supplementary Figure 1

(a) From config.yaml input file into Cobra

```
#Project Name
#Use in pca, sample-sample, sample-feature plot. Please use "_" to seperate different words
project: ChIP_seq
#enhancer option enhancer/promoter/all
enhancer: all
#Location of metasheet
metasheet: metasheet.csv
ref: "scripts/ref.yaml"
#Assembly is needed when seperate enhancer/promoter, motif finding, nearyby gene
assembly: hg19
#At least mini_num_sample should have RPKM > rpkm_threshold
rpkm threshold: 1
mini_num_sample: 0
#Scale method for the nomalize counts among samples
#z- z-score
#q- quantile-normalize
#l- log-transform
scale: q
#Fliter metric in feature selection
#sd- Standard deviation
#cov- Coefficient of Variation
#av- mean
filter-opt: cov
#top percent cutoff
filter-percent: 100
#limited of peaks to use for plot
SSpeaks: 2000000
SFpeaks: 2000000
#number of k-means clustering in sample-feature plot
num_kmeans_clust: 6
                                                                 Supplementary Figure 2a
```

(a) From config.yaml input file into Cobra


```
#correlation method for sample-sample, sample-feature plot
# "person" or "spearman"
cor_method: 'pearson'
#distance method for sample-sample, sample-feature plot
# "euclidean", "manhattan", "canberra", "binary", "maximum" or "minkowski"
dis_method: 'euclidean'
#DEseq_cut_off - Padj/LG2FC
Padj: 0.05
LG2FC: 0
#DEseq normalize method
#def - normlize by default setting of DEseq2
#depth - normlize by the sequence depth of each sample
nor_method: 'depth'
#Motif analysis - true/false
motif: 'false'
#BAM files sorted? true/false
bam_sort: 'true'
#CNV correction? true/false
CNV_correction: 'false'
#unchanged heatmap
unchanged_heatmap: 'false'
#fastq as input
fastq_in: 'true'
#number of threads used in bwa mem
thread: 8
                                                               Supplementary Figure 2b
```

(a) From config.yaml input file into Cobra

```
# sample names, e.g. "sample01" "sample02" can be any abitrary string
# HOWEVER, these names must match what is in metasheet.csv
# FOR each sample, define the path to the fastq file
fastq:
   sample1:

    ./XX1_R1.fastq.gz

   sample2:
       _ ./XX2_R1.fastq.gz
   input:
       - ./XX_input_R1.fastq.gz
# bed, bam and bigwig is not needed when fastq_in is true
bed:
   sample1: ./XX1.bed
sample2: ./XX2.bed
bam:
   sample1: ./XX1.bam
sample2: ./XX2.bam
bigwig:
    sample1: ./XX1.bw
    sample2: ./XX2.bw
# tab-separated cnv files
cnv:
   sample1: ./XX1.igv
sample2: ./XX2.igv
                                                                                    Supplementary Figure 2c
```



Supplementary Figure 3